The future challenges facing the development of new antimicrobial drugs

[1]  ACTIVITY IN VITRO , 2003 .

[2]  A. Coates.  Dormancy and low-growth states in microbial disease , 2003 .

[3]  B. Cunha.  Strategies to control antibiotic resistance. , 2002, Seminars in respiratory infections.

[4]  Michael D. Burkart,et al.  Biomimetic synthesis and optimization of cyclic peptide antibiotics , 2002, Nature.

[5]  Gurdyal S Besra,et al.  Current status and future development of antitubercular chemotherapy , 2002, Expert opinion on investigational drugs.

[6]  K. Gupta.  Addressing antibiotic resistance. , 2002, The American journal of medicine.

[7]  A. Driks.  Maximum shields: the assembly and function of the bacterial spore coat. , 2002, Trends in microbiology.

[8]  M. Rosenberg,et al.  Novel targets for the future development of antibacterial agents , 2002, Symposium series.

[9]  R. Wilson,et al.  What is finished, and why does it matter. , 2002, Genome research.

[10]  I Chopra,et al.  Exploiting current understanding of antibiotic action for discovery of new drugs , 2002, Symposium series.

[11]  W. Craig,et al.  Animal model pharmacokinetics and pharmacodynamics: a critical review. , 2002, International journal of antimicrobial agents.

[12]  L. Girard,et al.  Failure of Helicobacter pylori eradication: is poor compliance the main cause? , 2002, Gastroenterologie clinique et biologique.

[13]  A. Evangelista,et al.  Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  M. A. Strauch,et al.  Bacillus subtilis sporulation and stationary phase gene expression , 2002, Cellular and Molecular Life Sciences CMLS.

[15]  K. Watabe,et al.  Assembly and genetics of spore protective structures , 2002, Cellular and Molecular Life Sciences CMLS.

[16]  Xilin Zhao,et al.  Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. , 2002, The Journal of infectious diseases.

[17]  D. Green.  The bacterial cell wall as a source of antibacterial targets , 2002, Expert opinion on therapeutic targets.

[18]  T. Nyström,et al.  The universal stress protein paralogues of Escherichia coli are co‐ordinately regulated and co‐operate in the defence against DNA damage , 2002, Molecular microbiology.

[19]  G. Kahlmeter,et al.  Antibiotic Use and Escherichia coli Resistance Trends for Quinolones and Cotrimoxazole in Sweden , 2002, Scandinavian journal of infectious diseases.

[20]  A. Sefton.  Mechanisms of antimicrobial resistance: their clinical relevance in the new millennium. , 2002, Drugs.

[21]  T. File,et al.  Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. , 2002, The Journal of antimicrobial chemotherapy.

[22]  G. Moran,et al.  Staphylococcus aureus resistant to vancomycin--United States, 2002. , 2002, MMWR. Morbidity and mortality weekly report.

[23]  R. England,et al.  Increased expression of the multidrug efflux genes acrAB occurs during slow growth of Escherichia coli. , 2002, FEMS microbiology letters.

[24]  M. Rosenberg,et al.  Exploiting genomics to discover new antibiotics. , 2001, Trends in microbiology.

[25]  S. Belkin,et al.  Survival of enteric bacteria in seawater. , 2001, FEMS microbiology reviews.

[26]  K. Lewis,et al.  Biofilms and Planktonic Cells of Pseudomonas aeruginosa Have Similar Resistance to Killing by Antimicrobials , 2001, Journal of bacteriology.

[27]  Takaaki Ohtake,et al.  Innate antimicrobial peptide protects the skin from invasive bacterial infection , 2001, Nature.

[28]  M. Watve,et al.  How many antibiotics are produced by the genus Streptomyces? , 2001, Archives of Microbiology.

[29]  S. Levy,et al.  Carriage of antibiotic-resistant fecal bacteria in Nepal reflects proximity to Kathmandu. , 2001, The Journal of infectious diseases.

[30]  B. Dougherty,et al.  Finding drug targets in microbial genomes. , 2001, Drug discovery today.

[31]  T. Nyström.  Not quite dead enough: on bacterial life, culturability, senescence, and death , 2001, Archives of Microbiology.

[32]  A. Coates,et al.  Increased levels of sigJ mRNA in late stationary phase cultures of Mycobacterium tuberculosis detected by DNA array hybridisation. , 2001, FEMS microbiology letters.

[33]  M. Rosenberg,et al.  Delivering novel targets and antibiotics from genomics. , 2001, Current opinion in investigational drugs.

[34]  Mary Jane Ferraro,et al.  Linezolid resistance in a clinical isolate of Staphylococcus aureus , 2001, The Lancet.

[35]  K. Chow,et al.  Clinical course of peritonitis due to Pseudomonas species complicating peritoneal dialysis: a review of 104 cases. , 2001, Kidney international.

[36]  M. Millar,et al.  Carriage of antibiotic-resistant bacteria by healthy children. , 2001, The Journal of antimicrobial chemotherapy.

[37]  M. Graham,et al.  Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid , 2001, The Lancet.

[38]  Peter E. Nielsen,et al.  Bactericidal antisense effects of peptide–PNA conjugates , 2001, Nature Biotechnology.

[39]  M. Gilman,et al.  Expression and isolation of antimicrobial small molecules from soil DNA libraries. , 2001, Journal of Molecular Microbiology and Biotechnology.

[40]  K. Lewis,et al.  Riddle of Biofilm Resistance , 2001, Antimicrobial Agents and Chemotherapy.

[41]  B A Pfeifer,et al.  Biosynthesis of Complex Polyketides in a Metabolically Engineered Strain of E. coli , 2001, Science.

[42]  J. Lynch,et al.  Hospital-acquired pneumonia: risk factors, microbiology, and treatment. , 2001, Chest.

[43]  R. Leclercq.  Safeguarding future antimicrobial options: strategies to minimize resistance. , 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[44]  C. Sohaskey,et al.  Nonreplicating persistence of mycobacterium tuberculosis. , 2001, Annual review of microbiology.

[45]  A. Fleming,et al.  Classics in infectious diseases: on the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae by Alexander Fleming, Reprinted from the British Journal of Experimental Pathology 10:226-236, 1929. , 1980, Reviews of infectious diseases.

[46]  M. Cazzola,et al.  Parenteral antibiotic therapy in the treatment of lower respiratory tract infections. Strategies to minimize the development of antibiotic resistance. , 2000, Pulmonary pharmacology & therapeutics.

[47]  A. Bryskier,et al.  Novelties in the field of anti-infective compounds in 1999. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  G. Church,et al.  RNA expression analysis using a 30 base pair resolution Escherichia coli genome array , 2000, Nature Biotechnology.

[49]  P. Butcher,et al.  Detection of mRNA Transcripts and Active Transcription in Persistent Mycobacterium tuberculosisInduced by Exposure to Rifampin or Pyrazinamide , 2000, Journal of bacteriology.

[50]  I. Phillips,et al.  Antibiotic clinical trials revisited. , 2000, The Journal of antimicrobial chemotherapy.

[51]  R. Hare,et al.  Will genomics revolutionize antimicrobial drug discovery? , 2000, Current opinion in microbiology.

[52]  D. Mitchison.  Role of individual drugs in the chemotherapy of tuberculosis. , 2000, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[53]  J. Verhoef,et al.  The millennium bugs--the need for and development of new antibacterials. , 2000, International Journal of Antimicrobial Agents.

[54]  K. Lewis,et al.  Programmed Death in Bacteria , 2000, Microbiology and Molecular Biology Reviews.

[55]  C. Walsh.  Molecular mechanisms that confer antibacterial drug resistance , 2000, Nature.

[56]  F. Baquero,et al.  Mutation Frequencies and Antibiotic Resistance , 2000, Antimicrobial Agents and Chemotherapy.

[57]  P Lachmann,et al.  The Academy of Medical Sciences , 2018, The Grants Register 2019.

[58]  A. Opekun,et al.  Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study , 2000, Alimentary pharmacology & therapeutics.

[59]  F. Barchiesi,et al.  In vitro anti-cryptosporidial activity of cationic peptides alone and in combination with inhibitors of ion transport systems. , 2000, The Journal of antimicrobial chemotherapy.

[60]  B. Lazazzera,et al.  Quorum sensing and starvation: signals for entry into stationary phase. , 2000, Current opinion in microbiology.

[61]  Kenneth W. Bayles,et al.  The Staphylococcus aureus lrgAB Operon Modulates Murein Hydrolase Activity and Penicillin Tolerance , 2000, Journal of bacteriology.

[62]  J. Rosamond,et al.  Harnessing the power of the genome in the search for new antibiotics. , 2000, Science.

[63]  N. Wallis,et al.  The impact of genomics on novel antibacterial targets. , 2000, Current opinion in drug discovery & development.

[64]  D. Adam.  Short-course antibiotic therapy for infections with a single causative pathogen. , 2000, The Journal of international medical research.

[65]  I. Phillips,et al.  Antibiotic clinical trials—the Witley Park Symposium , 1999 .

[66]  D. Berrigan,et al.  Evolution in health and disease , 1999, Public health.

[67]  A. Alonso,et al.  Emergence of multidrug-resistant mutants is increased under antibiotic selective pressure in Pseudomonas aeruginosa. , 1999, Microbiology.

[68]  H. Lambert.  Don't keep taking the tablets? , 1999, The Lancet.

[69]  D. Kell,et al.  Stimulation of the multiplication of Micrococcus luteus by an autocrine growth factor , 1999, Archives of Microbiology.

[70]  S. Normark,et al.  Emergence of vancomycin tolerance in Streptococcus pneumoniae , 1999, Nature.

[71]  D. Wilkinson.  Eight years of tuberculosis research in Hlabisa--what have we learned? , 1999, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[72]  J. Mouton.  Combination therapy as a tool to prevent emergence of bacterial resistance , 1999, Infection.

[73]  J. Bennett,et al.  Constructing polyketides: from collie to combinatorial biosynthesis. , 1999, Annual review of microbiology.

[74]  C. Walsh,et al.  Harnessing the biosynthetic code: combinations, permutations, and mutations. , 1998, Science.

[75]  A. Allsop.  New antibiotic discovery, novel screens, novel targets and impact of microbial genomics. , 1998, Current opinion in microbiology.

[76]  H. Goossens,et al.  Decreasing antibiotic resistance of Enterobacteriaceae by introducing a new antibiotic combination therapy for neutropenic fever patients , 1998, Leukemia.

[77]  Claude Carbón,et al.  Regulating the use of antibiotics in the community , 1998, BMJ.

[78]  D B Kell,et al.  A bacterial cytokine. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[79]  A. Audurier,et al.  Pseudomonas aeruginosa from cystic fibrosis patients: study using whole cell RAPD and antibiotic susceptibility. , 1998, Pathologie-biologie.

[80]  R. Bax,et al.  Antibiotic resistance - what can we do? , 1998, Nature Medicine.

[81]  S. Solomon,et al.  Requirements for Infrastructure and Essential Activities of Infection Control and Epidemiology in Hospitals: A Consensus Panel Report , 1998, Infection Control & Hospital Epidemiology.

[82]  M. Spector.  The starvation-stress response (SSR) of Salmonella. , 1998, Advances in microbial physiology.

[83]  D. Mitchison.  How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[84]  W. Craig,et al.  Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men Tions Were Associated with Only a Slight Reduction in Bacterial , 2022 .

[85]  D. Andersson,et al.  Carbon starvation of Salmonella typhimurium does not cause a general increase of mutation rates , 1997, Journal of bacteriology.

[86]  D. Knowles,et al.  New strategies for antibacterial drug design. , 1997, Trends in microbiology.

[87]  A. Schaeffer.  Cotrimoxazole: rationale for re-examining its indications for use. , 1997, The Journal of urology.

[88]  B. Hall,et al.  Adaptive mutations produce resistance to ciprofloxacin , 1997, Antimicrobial agents and chemotherapy.

[89]  F. Baquero,et al.  Strategies to minimize the development of antibiotic resistance. , 1997, Journal of chemotherapy.

[90]  D. Mitchison.  Mechanisms of Tuberculosis Chemotherapy , 1997 .

[91]  A. Medeiros,et al.  Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics , 1997 .

[92]  W. Jb.  Drug efflux as a mechanism of resistance. , 1996 .

[93]  R. Moellering,et al.  Antimicrobial-drug resistance. , 1996, The New England journal of medicine.

[94]  P. Venkatesan,et al.  Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis , 1996, Antimicrobial agents and chemotherapy.

[95]  R. Hengge-aronis,et al.  Back to log phase: σS as a global regulator in the osmotic control of gene expression in Escherichia coli , 1996, Molecular microbiology.

[96]  J. Grange.  Mycobacteria and Human Disease , 1996 .

[97]  G. Poste,et al.  New approaches to the control of infections caused by antibiotic-resistant bacteria. An industry perspective. , 1996, JAMA.

[98]  R A Weinstein,et al.  Strategies to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in Hospitals. A challenge to hospital leadership. , 1996, JAMA.

[99]  J. B. Williams.  Drug efflux as a mechanism of resistance. , 1996, British journal of biomedical science.

[100]  F. Taddei,et al.  cAMP-dependent SOS induction and mutagenesis in resting bacterial populations. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[101]  S. Amyes,et al.  β-Lactam resistance in normal faecal flora from South Africa , 1995, Epidemiology and Infection.

[102]  E. Ishiguro,et al.  Direct correlation between overproduction of guanosine 3',5'-bispyrophosphate (ppGpp) and penicillin tolerance in Escherichia coli , 1995, Journal of bacteriology.

[103]  B. Spratt.  Resistance to antibiotics mediated by target alterations. , 1994, Science.

[104]  S. J. Knott,et al.  Effect of antibiotics on non-growing planktonic cells and biofilms of Escherichia coli. , 1994, The Journal of antimicrobial chemotherapy.

[105]  M. Flickinger,et al.  Starvation‐induced expression of SspA and SspB: the effects of a null mutation in sspA on Escherichia coli protein synthesis and survival during growth and prolonged starvation , 1994, Molecular microbiology.

[106]  D. Hopwood.  Genetic engineering of Streptomyces to create hybrid antibiotics. , 1993, Current opinion in biotechnology.

[107]  R. Wenzel,et al.  Trends in antimicrobial utilization at a tertiary teaching hospital during a 15-year period (1978-1992). , 1993, Infection control and hospital epidemiology.

[108]  J J Schentag,et al.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients , 1993, Antimicrobial Agents and Chemotherapy.

[109]  M. Barer,et al.  Factors affecting the selection and use of tetrazolium salts as cytochemical indicators of microbial viability and activity. , 1993, The Journal of applied bacteriology.

[110]  R. Mouton,et al.  Detection of penicillin tolerance in Streptococcus pyogenes. , 1993, Journal of medical microbiology.

[111]  T. Kilpi,et al.  Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines , 1992, The Lancet.

[112]  D. Livermore.  Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa , 1992, Antimicrobial Agents and Chemotherapy.

[113]  R. N. Walters,et al.  Bactericidal activities of five quinolones for Escherichia coli strains with mutations in genes encoding the SOS response or cell division , 1992, Antimicrobial Agents and Chemotherapy.

[114]  A. Kochi,et al.  Tuberculosis: a global overview of the situation today. , 1992, Bulletin of the World Health Organization.

[115]  G. Jacoby,et al.  More extended-spectrum beta-lactamases , 1991, Antimicrobial Agents and Chemotherapy.

[116]  S. Fesik,et al.  Role of protonated and neutral forms of macrolides in binding to ribosomes from gram-positive and gram-negative bacteria , 1990, Antimicrobial Agents and Chemotherapy.

[117]  T. Gootz.  Discovery and development of new antimicrobial agents , 1990, Clinical Microbiology Reviews.

[118]  C. Wa,et al.  Killing and regrowth of bacteria in vitro: a review. , 1990 .

[119]  A. Tomasz,et al.  Mechanism of phenotypic tolerance of nongrowing pneumococci to beta-lactam antibiotics. , 1990, Scandinavian journal of infectious diseases. Supplementum.

[120]  W. Craig,et al.  Killing and regrowth of bacteria in vitro: a review. , 1990, Scandinavian journal of infectious diseases. Supplementum.

[121]  E. Perez-stable,et al.  Current tuberculosis treatment regimens. Choosing the right one for your patient. , 1989, Clinics in chest medicine.

[122]  J. S. Daly,et al.  Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound , 1988, Antimicrobial Agents and Chemotherapy.

[123]  P. Davey,et al.  Tolerance of Pseudomonas aeruginosa to killing by ciprofloxacin, gentamicin and imipenem in vitro and in vivo. , 1988, The Journal of antimicrobial chemotherapy.

[124]  J. Smith.  The mode of action of 4-quinolones and possible mechanisms of resistance. , 1986, The Journal of antimicrobial chemotherapy.

[125]  A. Tomasz,et al.  Induction of autolysis in nongrowing Escherichia coli , 1986, Journal of bacteriology.

[126]  P. Byers,et al.  Gastrointestinal hemorrhage due to carcinoid tumors of the small intestine. , 1986, Journal of the American Medical Association (JAMA).

[127]  H. Ikeda,et al.  Production of new hybrid antibiotics, mederrhodins A and B, by a genetically engineered strain , 1986, Antimicrobial Agents and Chemotherapy.

[128]  H. Ikeda,et al.  Production of ‘hybrid’ antibiotics by genetic engineering , 1985, Nature.

[129]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[130]  H. Moyed,et al.  hipA, a newly recognized gene of Escherichia coli K-12 that affects frequency of persistence after inhibition of murein synthesis , 1983, Journal of bacteriology.

[131]  H. Neu.  Structure-Activity Relations of New β-Lactam Compounds and in Vitro Activity Against Common Bacteria , 1983 .

[132]  G. Eliopoulos,et al.  Antibiotic synergism and antimicrobial combinations in clinical infections. , 1982, Reviews of infectious diseases.

[133]  B. Spratt.  Biochemical and genetical approaches to the mechanism of action of penicillin. , 1980, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[134]  D. Mitchison.  Basic mechanisms of chemotherapy. , 1979, Chest.

[135]  John E. Bennett,et al.  Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .

[136]  J. Louvois.  The bacteriology and chemotherapy of brain abscess , 1978 .

[137]  S. Amyes,et al.  R-factor mediated dihydrofolate reductases which confer trimethoprim resistance. , 1978, Journal of general microbiology.

[138]  C. O'callaghan.  Irreversible Effects of Serum Proteins on Beta-Lactam Antibiotics , 1978, Antimicrobial Agents and Chemotherapy.

[139]  H. Neu,et al.  Cefuroxime, a Beta-Lactamase-Resistant Cephalosporin with a Broad Spectrum of Gram-Positive and -Negative Activity , 1978, Antimicrobial Agents and Chemotherapy.

[140]  E. Falsen,et al.  Characteristics of antibiotic-resistant Escherichia coli in the rectum of healthy school-children. , 1977, Journal of medical microbiology.

[141]  P. Dineen,et al.  Tuberculous Peritonitis: 43 Years' Experience in Diagnosis and Treatment , 1976, Annals of surgery.

[142]  R. Sykes,et al.  The -lactamases of Gram-negative bacteria and their rle in resistance to -lactam antibiotics , 1976 .

[143]  C. O'callaghan,et al.  Cefuroxime, a New Cephalosporin Antibiotic: Activity In Vitro , 1976, Antimicrobial Agents and Chemotherapy.

[144]  H. Immich.  Letter: Rauwolfia derivatives and cancer. , 1974, Lancet.

[145]  D. Smith,et al.  Recovery of resistance factors from a drug-free community. , 1969, Lancet.

[146]  J. Gurney.  Recovery of resistance factors from a drug-free community. , 1970, The Lancet.

[147]  W. Wehrli,et al.  Interaction of rifamycin with bacterial RNA polymerase. , 1968, Proceedings of the National Academy of Sciences of the United States of America.

[148]  W. Mcdermott,et al.  Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. , 1966 .

[149]  R. Austrian,et al.  PNEUMOCOCCAL BACTEREMIA WITH ESPECIAL REFERENCE TO BACTEREMIC PNEUMOCOCCAL PNEUMONIA. , 1964, Annals of internal medicine.

[150]  D. D. Woods.  The Relation of p-aminobenzoic Acid to the Mechanism of the Action of Sulphanilamide. , 1940 .

[151]  C. Aring,et al.  A CRITICAL REVIEW , 1939, Journal of neurology and psychiatry.

[152]  A. Fleming,et al.  On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzæ , 1929 .